Abstract Number: 2471 • 2017 ACR/ARHP Annual Meeting
Sustained Response in a Phase 3 Study of Sarilumab Plus Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients with Active, Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
Background/Purpose: Sarilumab is a human mAb blocking the IL-6Rα. In the phase 3 TARGET study (NCT01709578), sarilumab (150 or 200 mg subcutaneously [SC] every 2…Abstract Number: 2472 • 2017 ACR/ARHP Annual Meeting
Integrated Phase 3 Safety Results of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis
Background/Purpose: Sirukumab (SIR), a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, is in development for rheumatoid arthritis (RA) in…Abstract Number: 2473 • 2017 ACR/ARHP Annual Meeting
Sirukumab Subcutaneous Dose Regimens Maintain Clinical Response over Dosing Intervals in Rheumatoid Arthritis Patients: Results from a Phase 3 Study
Background/Purpose: Sirukumab (SIR), a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, has demonstrated efficacy in rheumatoid arthritis (RA)…Abstract Number: 2474 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Extending Tocilizumab Infusion Intervals from 4 Weeks to 6 Weeks in Patients with Rheumatoid Arthritis
Background/Purpose : A period of 4 weeks (w) has been recommended for rheumatoid arthritis (RA) patients as the interval between tocilizumab (TCZ, 8mg/kg) infusions. However,…Abstract Number: 2475 • 2017 ACR/ARHP Annual Meeting
Clinical Remission in Subjects with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab As Monotherapy or in Combination with Methotrexate or Other Synthetic Dmards: A Real-World Clinical Trial
Background/Purpose: the primary objective of this study was to assess the 24-week efficacy and safety of subcutaneous (SC) tocilizumab (TCZ) 162 mg weekly (qw) as…Abstract Number: 2476 • 2017 ACR/ARHP Annual Meeting
Assessment of Dose Dependent Effects of Vobarilizumab, an Anti-IL6 Receptor (IL-6R) Nanobody®, on Systemic Biomarkers in Patients with Moderate-to-Severe Rheumatoid Arthritis (RA): Results of Two Phase 2b Studies
Background/Purpose: Vobarilizumab is a Nanobody consisting of an anti-IL-6R domain and an anti-human serum albumin domain in development for treatment of rheumatoid arthritis (RA) and…Abstract Number: 2477 • 2017 ACR/ARHP Annual Meeting
Descriptive Patterns of Switches and Swaps in Patients with Rheumatoid Arthritis Initially Treated with Anti-TNF Agents in First Intention between 2000 and 2006, and 2007 and 2015 – Experience from a Real-World Database RHUMADATA®
Background/Purpose: Between 2000 and 2006, the only other treatment option for patients with rheumatoid arthritis (RA) first exposed to an anti-TNF agent was another anti-TNF…Abstract Number: 2478 • 2017 ACR/ARHP Annual Meeting
Retention on Adalimumab, Etanercept, Golimumab and Infliximab in Two Eras – Experience of Patients with Rheumatoid Arthritis from a Real-World Database RHUMADATA®
Background/Purpose: Anti-TNFs have been used to treat RA since 2000. Since the availability of new agents with different mechanisms of action around 2007, the pattern…Abstract Number: 2479 • 2017 ACR/ARHP Annual Meeting
Duration of Response in a Phase 3 Study of Sarilumab Plus Methotrexate in Patients with Active, Moderate-to-Severe Rheumatoid Arthritis
Background/Purpose: Sarilumab is a human mAb blocking the IL-6Rα. In the phase 3, 52-week MOBILITY study (NCT01061736), sarilumab (150 or 200 mg subcutaneously every 2…Abstract Number: 2480 • 2017 ACR/ARHP Annual Meeting
Improvements in Remission and Low Disease Activity Are Achieved with Ongoing Sarilumab Treatment, in Patients with Rheumatoid Arthritis in 2 Phase 3 Studies
Background/Purpose: Sarilumab is a human mAb blocking the IL-6Rɑ. Efficacy and safety of sarilumab (150 or 200 mg subcutaneously every 2 wks [q2w]) + conventional…Abstract Number: 2481 • 2017 ACR/ARHP Annual Meeting
Long-Term Safety of Adalimumab (HUMIRA) in Adult Patients from Global Clinical Trials across Multiple Indications: An Updated Analysis in 29,987 Patients Representing 56,951 Patient-Years
Background/Purpose: Adalimumab is an anti–tumor necrosis factor-α (TNF-α) agent indicated for the treatment of immune-mediated diseases. The long-term safety of adalimumab was previously reported in…Abstract Number: 2482 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Switching from Adalimumab to Sarilumab in an Open-Label Extension of a Phase 3 Monotherapy Trial in Patients with Active Rheumatoid Arthritis
Background/Purpose: Sarilumab is a human mAb blocking the IL-6Rα. Efficacy and safety of sarilumab as monotherapy and combination therapy have been reported.1-3 In MONARCH (NCT02332590),…Abstract Number: 2483 • 2017 ACR/ARHP Annual Meeting
Cycling Versus Swapping in Patients with Rheumatoid Arthritis with an Inadequate Response to at Least One Tumor Necrosis Factor Alpha Inhibitor: A Systematic Review and Meta-Analysis of Observational Studies
Background/Purpose: In patients with rheumatoid arthritis (RA) who do not respond or lose response to a tumor necrosis factor inhibitor (TNFi), opinions are divided on…Abstract Number: 2484 • 2017 ACR/ARHP Annual Meeting
When Etanercept Switch Fails – Clinical Considerations
Background/Purpose: On January 14th 2016 EMA approved the biosimilar Etanercept (SB4, Benepali) for clinical use. A non-medical switch from originator Etanercept (ETA, Enbrel) to SB4…Abstract Number: 2485 • 2017 ACR/ARHP Annual Meeting
Outcomes of Switching from TNF Inhibitors to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events
Background/Purpose: Tumor necrosis factor alpha (TNFα) inhibitors have been used to treat rheumatoid arthritis (RA) for >10 years. The outcomes has revolutionized the treatment goal…
ACR Meeting Abstracts